Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
UNITED LABORATORIES (03933.HK) Dupilumab Injection Receives Implied Approval for Clinical Trial
Recommend 2 Positive 2 Negative 0 |
||||
|
||||
|
UNITED LABORATORIES (03933.HK) announced that the atopic dermatitis indication for the dupilumab biosimilar injection developed by its wholly owned subsidiary, Zhuhai United, has obtained implied approval for clinical trials from the National Medical Products Administration of China. Dupilumab is a fully human immunoglobulin G4 monoclonal antibody used for the treatment of atopic dermatitis, particularly in patients with moderate-to-severe atopic dermatitis whose condition is inadequately controlled by topical therapies or for whom topical therapies are not advisable. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
